Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerg...

Full description

Bibliographic Details
Main Authors: Al-Atrash, G. (Author), Black, K.L (Author), Cai, T. (Author), Cavazos, A. (Author), Ciurea, S. (Author), Filipe, S. (Author), Galetto, R. (Author), Gouble, A. (Author), Gu, J. (Author), Guzman, M.L (Author), Han, L. (Author), Kantarjian, H. (Author), Konoplev, S. (Author), Konopleva, M. (Author), Kuruvilla, V. (Author), Lane, A.A (Author), Liu, C.-G (Author), Liu, X. (Author), Ma, H. (Author), Naqvi, A.S (Author), Neelapu, S.S (Author), Pemmaraju, N. (Author), Skwarska, A. (Author), Smith, J. (Author), Su, X. (Author), Sugita, M. (Author), Tang, G. (Author), Taylor, D. (Author), Thomas-Tikhonenko, A. (Author), Weng, C. (Author), Yuan, Q. (Author), Zhang, Q. (Author), Zhao, M. (Author)
Format: Article
Language:English
Published: Nature Research 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items